Hot on the heels of the release of a study demonstrating the cost-saving potential of Wyeth-Lederle's heptavalent pneumococcal conjugate vaccine ['Prevnar'],1researchers at the 5th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced more good news for the vaccine product. According to the results of their modelling study, routine vaccination of children aged <5 years againstStreptococcus pneumoniaewould substantially reduce the costs of medical treatment and lost productivity related to pneumococcal disease.2These findings have importance for health-care payers and societies worldwide, sinceS. pneumoniaeis a leading cause of meningitis, bacteraemia, pneumonia, otitis media and sinusitis - diseases which represent a significant economic burden.